The Future of Human Optimization

welcome to the future of human optimization January 8, 2021 The information contained in this presentation is provided by Optimi Health Corp. (“Optimi” or the All of the forward-looking statements and information contained in this presentation speak only as of “Company”) for informational purposes only and does not constitute an offer to issue or arrange to the date of this presentation and are expressly qualifi ed by the foregoing cautionary statements. The issue, or the solicitation of an over to issue, securities of Optimi or other fi nancial products. Company expressly disclaims any obligation to update or alter statements containing any forward- looking statements, or the factors or assumptions underlying them, whether as a result of new Prospective investors should rely only on the information contained in the preliminary prospectus information, future events or otherwise, except as required by applicable law. of Optimi. Health Corp. (the “Company” or “Optimi”) dated December 28, 2020 (the “Prospectus”). This presentation is qualifi ed in its entirety by reference to, and must be read in conjunction with, the Reference to Prospectus information contained in the Prospectus. A prospective investor is not entitled to rely on parts of the The information contained in this presentation does not purport to be all inclusive or to contain all information contained in this presentation to the exclusion of others. The Company and Mackie Research information that a prospective investor may require. Prospective investors are encouraged to conduct Capital Corporation, Canaccord Capital Corporation and Stifel Nicolaus Canada Inc. (the “Agents”) have their own analyses and reviews of the Company and of the information contained in this presentation. not authorized anyone to provide prospective purchasers with this presentation. Except as specifi cally Without limitation, prospective investors should consider the advice of their fi nancial, legal, accounting, provided herein, this presentation may not be copied or otherwise distributed, in whole or in part, by tax and other advisors and such other factors that they consider appropriate in investigating and or to any person or in any medium whatsoever. Any unauthorized use of the presentation is analyzing the Company. A preliminary prospectus containing important information relating to the strictly prohibited. securities described in this document has been fi led with the securities regulatory authorities in each of the provinces of Canada, excluding Quebec. A copy of the preliminary prospectus, and any amendment, Forward-Looking Information is required to be delivered with this document. The preliminary prospectus is still subject to completion. Certain statements contained in this presentation constitute forward-looking statements and forward- There will not be any sale or any acceptance of an offer to buy the securities until a receipt for the fi nal looking information (collectively, “forward-looking statements”). Such forward-looking statements relate prospectus has been issued. This document does not provide full disclosure of all material facts relating to possible events, conditions or fi nancial performance of the Company based on future economic to the securities offered. Investors should read the preliminary prospectus, the fi nal prospectus and conditions and courses of action. All statements other than statements of historical fact are forward- any amendment for disclosure of those facts, especially risk factors relating to the securities offered, looking statements. The use of any words or phrases such as “seek,” “anticipate”, “plan”, “continue”, before making an investment decision. A copy of the prospectus, and any amendments, is required to be “estimate”, “expect”, “may”, “will”, “project”, “predict”, “potential”, “targeting”, “intend”, “could”, “might”, delivered with this document. Copies of the prospectus may be obtained from (i) www.sedar.com or (ii) Legal Disclaimer Legal “should”, “believe”, “will likely result”, “are expected to”, “will continue”, “is anticipated”, “believes”, Mackie Research Capital Corp., Canaccord Genuity Corp. or Stifel Nicolaus Canada Inc. “estimated”, “intends”, “plans”, “projection”, “outlook” and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements include, among others, statements Third-Party Information pertaining to the Company’s proposed business involving psilocybin, the proposed CSE listing, the size This presentation includes market and industry data obtained from various publicly available sources of the Offering, completion of the Offering, the anticipated Offering Price, the use of the net proceeds and other sources believed by the Company to be true. Although the Company believes it to be reliable, of the Offering and Optimi’s plans, focus and objectives, the Company’s assessment of, and targets for, the Company has not independently verifi ed any of the data from third- party sources referred to in this sales of mushroom derived products, expansion of platforms through which the Company’s products presentation or analyzed or verifi ed the underlying reports relied upon or referred to by such sources, or may be sold, expansion of the Company’s distribution channels, the impact of strategic partnerships on ascertained the underlying assumptions relied upon by such sources. The Company does not make any the Company’s business and fi nancial condition, anticipated product category growth, and online sales. representation as to the accuracy of such information. Some numbers in this presentation may not be These statements involve known and unknown risks, assumptions, uncertainties, and other factors that exact or add consistently due to rounding. may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Electronic Form This presentation may have been sent to you in an electronic form. You are reminded that documents Forward-looking statements are based on the opinions and estimates of management at the date the transmitted via this medium may be altered or changed during the process of electronic transmission. statements are made, and are subject to a variety of risks and uncertainties and other factors that You are responsible for protecting against viruses and other destructive items. Your receipt of this could cause actual events or results to differ materially from those anticipated in the forward-looking electronic transmission is at your own risk and it is your responsibility to take precautions to ensure that statements, including, among others, the Company’s partnership with license holders that project it is free from viruses and other items of a destructive nature. As a consequence of the above, neither the certain crop yields; product liability; government regulation; the Company’s expansion plans; the adverse Company nor any director, offi cer, employee or agent of any of them or any affi liate of any such person impact of the COVID-19 pandemic to the Company’s operations, supply chain, distribution chain and to accepts any liability or responsibility whatsoever in respect of any difference between the document the broader market for and customers of the Company’s products; the impact of global conditions and distributed to you in electronic format and the hard copy version that may be made available to you. unemployment rates on the Company’s stakeholders; general economic and fi nancial conditions; product acceptance and competing products; internet and system infrastructure functionality; information Safe Harbor technology security; cash available to fund operations; crop risk; availability of capital; changes in This presentation does not constitute an offer of shares for sale in the United States or to any person customer demand; and others set out in the Company’s preliminary prospectus available at www.sedar. that is, or is acting for the account or benefi t of, any U.S. person as defi ned in Regulation S under the com. The Company believes there is a reasonable basis for the expectations refl ected in the forward- United States Securities Act of 1933, as amended (the “Securities Act”) or in any other jurisdiction in looking statements; however, no assurance can be given that these expectations and the underlying which such an offer would be illegal. The Company’s securities have not been and will not be registered opinions, estimates, and assumptions will prove to be correct. The forward-looking statements included under the Securities Act. We seek safe harbor. in this presentation should not be unduly relied upon by investors. Investor Deck 2021 2 Highlights STRATEGIC EXCEPTIONAL EXPERIENCED PREMIUM BUSINESS CULTIVATION & PASSIONATE NUTRACEUTICALS ADVANTAGES FACILITIES TEAM CTC OPPORTUNITY • Vertically integrated operation: • In-house Health Canada consulting • Strong Advisory Team supporting all • Submitted NPN applications for Cultivation to Consumer (CTC) key aspects of the business fi rst 7 product offerings • Submitted Health Canada Dealers • Potential multi-revenue generating License Application for large scale • Experienced Management team • Supplement line has been assets: E-Commerce, Two permitted Psilocybin Cultivation in cultivation, fi nance, nutraceutical manufactured & tested - launching & completed building shells distribution, wholesale, and retail Q1 2021 • Two 10,000 sq. ft. (each) GMP • International sales and growth & EU GMP-capable facilities under • Agreement to work with • Early entry

Load more